a Human Retrovirus Pathogenesis Section, Center for Cancer Research, National Cancer Institute at Frederick , Frederick , MD , USA.
b Human Retrovirus Section, Vaccine Branch, Center for Cancer Research , National Cancer Institute at Frederick , Frederick, Frederick , MD , USA.
Hum Vaccin Immunother. 2018;14(9):2163-2177. doi: 10.1080/21645515.2018.1489949. Epub 2018 Jul 12.
HIV sequence diversity and the propensity of eliciting immunodominant responses targeting inessential variable regions are hurdles in the development of an effective AIDS vaccine. We developed a DNA vaccine comprising conserved elements (CE) of SIV p27 and HIV-1 Env and found that priming vaccination with CE DNA is critical to efficiently overcome the dominance imposed by Gag and Env variable regions. Here, we show that DNA vaccinated macaques receiving the CE prime/CE+full-length DNA co-delivery booster vaccine regimens developed broad, potent and durable cytotoxic T cell responses targeting conserved protein segments of SIV Gag and HIV Env. Gag CE-specific T cells showed robust anamnestic responses upon infection with SIV which led to the identification of CE-specific cytotoxic lymphocytes able to recognize epitopes covering distinct CE on the surface of SIV infected cells in vivo. Though not controlling infection overall, we found an inverse correlation between Gag CE-specific CD8 T cell responses and peak viremia. The T cell responses induced by the HIV Env CE immunogen were recalled in some animals upon SIV infection, leading to the identification of two cross-reactive epitopes between HIV and SIV Env based in sequence homology. These data demonstrate that a vaccine combining Gag and Env CE DNA subverted the normal immunodominance patterns, eliciting immune responses that included subdominant, highly conserved epitopes. These vaccine regimens augment cytotoxic T cell responses to highly conserved epitopes in the viral proteome and maximize response breadth. The vaccine-induced CE-specific T cells were expanded upon SIV infection, indicating that the predicted CE epitopes incorporated in the DNA vaccine are processed and exposed by infected cells in their natural context within the viral proteome.
HIV 序列多样性和引发针对非必需可变区免疫优势反应的倾向是开发有效 AIDS 疫苗的障碍。我们开发了一种包含 SIV p27 和 HIV-1Env 的保守元件(CE)的 DNA 疫苗,发现用 CE DNA 进行初始疫苗接种对于有效地克服 Gag 和 Env 可变区施加的优势至关重要。在这里,我们表明,接受 CE 引/CE+全长 DNA 共递加强化疫苗方案的 DNA 接种猕猴发展了针对 SIV Gag 和 HIV Env 保守蛋白片段的广泛、有效和持久的细胞毒性 T 细胞反应。Gag CE 特异性 T 细胞在感染 SIV 后表现出强烈的回忆反应,从而鉴定出能够识别体内 SIV 感染细胞表面不同 CE 上的 CE 特异性细胞毒性淋巴细胞表位。虽然总体上不能控制感染,但我们发现 Gag CE 特异性 CD8 T 细胞反应与峰值病毒血症呈反比。在一些动物中,HIV Env CE 免疫原在 SIV 感染时会引起 T 细胞反应的回忆,从而在序列同源性的基础上鉴定出 HIV 和 SIV Env 之间的两个交叉反应表位。这些数据表明,一种结合 Gag 和 Env CE DNA 的疫苗颠覆了正常的免疫优势模式,引发了包括亚优势、高度保守表位在内的免疫反应。这些疫苗方案增强了对病毒蛋白组中高度保守表位的细胞毒性 T 细胞反应,并最大限度地增加了反应广度。在 SIV 感染后,疫苗诱导的 CE 特异性 T 细胞得到扩增,表明预测的 DNA 疫苗中包含的 CE 表位在其天然的病毒蛋白组内被感染细胞加工和暴露。